Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adma Biologics (NQ: ADMA )

21.30 -0.07 (-0.33%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,190,136
Open 21.60
Bid (Size) 20.99 (1)
Ask (Size) 21.25 (5)
Prev. Close 21.37
Today's Range 20.87 - 21.70
52wk Range 3.600 - 23.64
Shares Outstanding 196,357,149
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioNTech Stock Got A IBD RS Rating Lift
A Relative Strength Rating upgrade for BioNTech ADR shows improving technical performance. 
Via Investor's Business Daily
ADMA BIOLOGICS ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on Behalf of ADMA Biologics Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire

Performance

YTD
+368.13%
+368.13%
1 Month
+36.36%
+36.36%
3 Month
+19.39%
+19.39%
6 Month
+121.18%
+121.18%
1 Year
+440.61%
+440.61%

More News

Read More
While growth is established for NASDAQ:ADMA, the stock's valuation remains reasonable.
Via Chartmill
Vericel Stock Sees RS Rating Shoot Higher
Via Investor's Business Daily
Kirby McInerney LLP Reminds ADMA Biologics, Inc. (ADMA) Investors of Shareholder Investigation
From Kirby McInerney LLP
Via Business Wire
(ADMA) - Analyzing ADMA Biologics's Short Interest
Via Benzinga
Key Takeaways From ADMA Biologics Analyst Ratings
Via Benzinga
ADMA Biologics Announces Third Quarter 2024 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against ADMA Biologics, Inc. (ADMA)
From Kirby McInerney LLP
Via Business Wire
ADMA Investors Have Opportunity to Join ADMA Biologics, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
This Is What Whales Are Betting On ADMA Biologics
Via Benzinga
IBD 50's Top Stock, ADMA Biologics, Crashes After Auditor Unexpectedly Resigns
Via Investor's Business Daily
Buckle Up And Use Volitility To Your Advantage
Via Talk Markets
What You Missed On Wall Street This Past Friday
Via Talk Markets
Amazon Posts Upbeat Results, Joins Cardinal Health, Waters, Atlassian, Charter Communications, MasTec And Other Big Stocks Moving Higher On Friday
Via Benzinga
ADMA Biologics, A Top 1% Stock, Skyrockets After Settling Its Accounting Debacle
Via Investor's Business Daily
ADMA Biologics to Report Third Quarter 2024 Financial Results on November 7, 2024
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into ADMA Biologics Inc and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into ADMA Biologics Inc and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Bragar Eagel & Squire, P.C. Is Investigating ADMA Biologics, Napco, and L&W and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ADMA BIOLOGICS ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on Behalf of ADMA Biologics Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade
Via Investor's Business Daily
Alkermes Stock Jumps Nearly 30% In 3 Months Amid Hefty Profits
Via Investor's Business Daily
CVS Has 'Real Value,' Jim Cramer Says: Micron Had An 'Amazing' Quarter
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.